Clinical Trial Update: Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intraoral administration of botulinum toxin A (Botox) for dentoalveolar neuropathic pain has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Isabel Moreno Hay | Conditions: Neuropathic Pain | Phase 2 | Status: COMPLETED